policy implications for medication treatment for opioid use disorder · 2018-07-18 · objectives...
TRANSCRIPT
![Page 1: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/1.jpg)
Policy implications for Medication treatment
for Opioid Use DisorderA Project RAMP Resource
Adam J. Gordon, MD MPH FACP DFASAM CMROJanuary 2018
![Page 2: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/2.jpg)
CONFLICT OF INTEREST AND DISCLOSURE
• Dr. Gordon has no fiduciary conflicts of interest• Some of the material presented herein has been previously published
from work at the University of Pittsburgh, University of Utah, and the Veterans Health Administration
• The views expressed in this presentation are Dr. Gordon’s and do not necessarily reflect the position or policy any institution, agency, or government
• Buprenorphine (BUP) = buprenorphine + naloxone unless otherwise stated
![Page 3: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/3.jpg)
OBJECTIVES
• Introduce clinical perspectives of opioid use, misuse, and opioid use disorder
• Provide a rationale introducing addiction treatment into health care environments (and primary care environments)
• Discuss policy issues associated with opioid use disorder treatment
![Page 4: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/4.jpg)
INTRODUCTIONS
![Page 5: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/5.jpg)
What is addiction?
![Page 6: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/6.jpg)
ADDICTION IS A BRAIN DISEASE
![Page 7: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/7.jpg)
DSM5 OPIOID USE DISORDER
1. Failure to fulfill role obligations at work, school, or home2. Recurrent use in hazardous situations3. Continued use despite substance-related social or interpersonal problems4. Tolerance5. Withdrawal/physical dependence6. Loss of control over amount of substances consumed7. Preoccupation with controlling substance use8. Preoccupation with substance use activities9. Impairment of social, occupational, or recreational activities 10. Use is continued despite persistent problems related to substance use11. Craving or a strong desire to use a substance
American Psychiatric Association, DSM-V 2013
Criteria:2-3 (mild)4-5 (moderate)6 or more (severe)
![Page 8: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/8.jpg)
Who is a typical person with addiction?
![Page 9: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/9.jpg)
![Page 10: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/10.jpg)
What is an opioid?
![Page 11: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/11.jpg)
![Page 12: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/12.jpg)
SIMPLE:
• Prescription pain medications• Naturally occurring substances• Synthetic substances
• Illicitly used• Prescription pain medications
![Page 13: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/13.jpg)
Compton WM. NEJM. 2016
![Page 14: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/14.jpg)
Compton WM. NEJM. 2016
![Page 15: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/15.jpg)
Youth: Some staggering numbers
• ~ 70% of high school students tried alcohol• ~ 50% will have taken an illegal drug• ~ 40% will have smoked a cigarette
• ~ 14%-20% will have used a prescription drug for a nonmedical purpose in prior year
• 72% of those with non-medical use obtained them from home (6% from friends)
Johnston LD, et.al. Monitoring the Future National results on Adolescent drug use: Overview of Key findings, 2013 NIH/NIDA, Principles of Adolescent Substance Use Disorder Treatment: A Research-Based Guide, 2014
Ontario Student Drug Use and Health Survey, 2011Brands B et.al. Nonmedical use of opioid analgesics among Ontario students. Canadian Family Physician. Vol 56. 256-62. March 2010
![Page 16: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/16.jpg)
Adolescents TREATED Differ from Adults in Substances Most Abused
SAMHSA, Center for Behavioral Statistics and Quality, NSDUH, 2013NIH/NIDA, Principles of Adolescent Substance Use Disorder Treatment: A Research-Based Guide, 2014
![Page 17: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/17.jpg)
OverDose Deaths in the US (Today)
www.cdc.gov
![Page 18: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/18.jpg)
So There is a Problem:
How do you fix it?
![Page 19: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/19.jpg)
www.cdc.gov
![Page 20: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/20.jpg)
Is Addiction a Primary Care problem?
• Opioids are “environmentally available”• drastic increases in the number of prescriptions written and dispensed
• From 76 million to 207 million (1991 to 2013) • aggressive marketing by pharmaceutical industry• greater social acceptability for using medications for different purposes
Volkow ND, presentation to the Senate Caucus on International Narcotics Control, 2014
![Page 21: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/21.jpg)
• CDC
![Page 22: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/22.jpg)
Not all on the patient!Providers need to face reality…
• Dated providers• Duped providers• Dishonest providers• Disabled providers• Medication mania• Hypertrophied enabling• Confrontation phobia
![Page 23: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/23.jpg)
Office-Based Settings for Addiction
• Addiction treatment for can be provided in office-based settings similar to treatments for
• Like other medical and mental health disorders
• Barriers to initiate or provide addiction care occur when providers in office-based settings attempt to make these environments “feel” like formal substance abuse treatment program environments
• These environments are different!• It hard to replicate an addiction treatment environment• “Keep it simple” and “grow from experience”
![Page 24: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/24.jpg)
Move from Education to Integration
• Change the culture• Team care and at least interdisciplinary approaches• Addiction is important and must be addressed
• Empower all providers to address addiction• Active training and retraining of wrap around services
• Physician targets • Primary care addiction expertise (ABAM/ASAM)• Encourage buprenorphine waivered clinicians • Offer pharmacotherapy
• Address “vulnerability” in specialized clinics • Provide easy linkages to addiction and mental health care• Don’t build a new system of care, do what you do but do it for patients with
addiction
![Page 25: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/25.jpg)
Move from Education to Integration
• Integration and Coordination of Care is important• Addiction occurs in a variety of settings• Pain and addiction competency should be universal• Integration of pain and addiction services into Primary Care is important
• BUT CHALLENGING !!!
• No easy answers to patient complexity• Addiction impacts health and healthcare engagement• Big gaps in the evidence-base on pain and addiction and how to
address concurrent problems• Patient centered care is important
![Page 26: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/26.jpg)
Primary Care Environment
![Page 27: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/27.jpg)
Time to step up…
Can Substance Use Disorders be Managed Using the Chronic Care
Model?
Review and Recommendations from a NIDA Consensus Group
McLellan. Public Health Reviews, 2014
![Page 28: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/28.jpg)
How do you treat Opioid Use Disorder?
![Page 29: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/29.jpg)
Scientifically Based Non-Pharmacologic Approaches to Addiction Treatment
• Brief Interventions (BIs)• Cognitive-behavioral therapy (CBT)• Community reinforcement (CR)• Motivational enhancement therapy (MET)• Contingency management (CM)• Systems treatment
• Behavioral couples therapy• Multidimensional family therapy
• 12-step facilitation (TSF)NIDA, 1999 and Onken L, 2002
![Page 30: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/30.jpg)
![Page 31: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/31.jpg)
![Page 32: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/32.jpg)
Buprenorphine Products
• Buprenorphine (2002 approved)• Indication: Opioid use disorder• Tablets available
• Buprenorphine/Naloxone (2002 approved)• Indication: Opioid use disorder• SL/Buccal Tablets and Film available
• Buprenorphine IV (1981 approved) • Indication: Pain
• Buprenorphine Patches (2010 approved) • Indication: Pain
• Buprenorphine Implants (2016 approved) • Indication: Opioid use disorder
• Buprenorphine Depot Injections (Under review)• Indication: Opioid use disorder
![Page 33: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/33.jpg)
In the Veterans Administration…
![Page 34: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/34.jpg)
Buprenorphine Works
Fiellin et.al. NEJM. 2015
![Page 35: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/35.jpg)
Dick AW, et.al. Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002–11. Health Affairs. 2015
No Help!
Helps!
![Page 36: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/36.jpg)
What is the relationship
between prescription
opioid use and heroin?
![Page 37: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/37.jpg)
![Page 38: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/38.jpg)
Is reducing the supply of opioids
the answer?
![Page 39: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/39.jpg)
![Page 40: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/40.jpg)
![Page 41: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/41.jpg)
Will control of opioids
prescribed help?
![Page 42: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/42.jpg)
![Page 43: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/43.jpg)
Kertesz S. Substance Abuse. 2017
![Page 44: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/44.jpg)
Barriers to Care - 1
• COMPLEXITY OF CARE FOR PATIENTS WITH ADDICTIONS
![Page 45: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/45.jpg)
Barriers to Care - 2
• PROVIDER STIGMA
![Page 46: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/46.jpg)
Barriers to Care - 3
• TIME & REIMBURSEMENT
![Page 47: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/47.jpg)
Barriers to Care - 4
• PATIENT FEARS & NOTIONS
![Page 48: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/48.jpg)
Facilitators of Integration - 1
• PROMOTE PATIENT-CENTERED ENGAGEMENT
![Page 49: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/49.jpg)
Facilitators of Integration - 2
PAIN & ADDICTION PROVIDER EDUCATION
![Page 50: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/50.jpg)
Facilitators of Integration - 3
• INTEGRATED SYSTEMS and RECORD SHARING
![Page 51: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/51.jpg)
Facilitators of Integration - 4
• ELIMINATE SILOS of CARE & PROMOTE INTERDISCIPLINARITY
![Page 52: Policy implications for Medication treatment for Opioid Use Disorder · 2018-07-18 · OBJECTIVES • Introduce clinical perspectives of opioid use, misuse, and opioid use disorder](https://reader034.vdocument.in/reader034/viewer/2022050411/5f888899685d664f6233f473/html5/thumbnails/52.jpg)
DISCUSSION
Further questions, please contact me!
[email protected] or [email protected]
Or contact the Project RAMP office…